Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Foghorn Therapeutics Inc
(NQ:
FHTX
)
6.260
+0.060 (+0.97%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
65,162
Open
6.200
Bid (Size)
6.000 (1)
Ask (Size)
9.820 (2)
Prev. Close
6.200
Today's Range
6.010 - 6.410
52wk Range
2.700 - 8.620
Shares Outstanding
36,936,886
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
August 08, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
-2.95%
-2.95%
1 Month
+3.64%
+3.64%
3 Month
+4.33%
+4.33%
6 Month
+5.92%
+5.92%
1 Year
-20.76%
-20.76%
More News
Read More
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
May 28, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
May 22, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics: Q4 Earnings Insights
March 07, 2024
Via
Benzinga
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
May 20, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 06, 2024
Via
InvestorPlace
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
May 06, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
April 16, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
April 09, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
April 05, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
March 26, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q4 2023
March 07, 2024
Via
InvestorPlace
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
March 07, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
March 05, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
February 28, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
February 08, 2024
Via
Benzinga
Why Foghorn Therapeutics (FHTX) Stock Is Exploding Higher
February 08, 2024
Via
Benzinga
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
February 08, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
January 08, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Announces CFO Departure
January 03, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting
December 01, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
November 02, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
October 24, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress
October 13, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.